JP6158833B2 - ベータ−カテニン関連疾患を処置するための有機組成物 - Google Patents

ベータ−カテニン関連疾患を処置するための有機組成物 Download PDF

Info

Publication number
JP6158833B2
JP6158833B2 JP2014551706A JP2014551706A JP6158833B2 JP 6158833 B2 JP6158833 B2 JP 6158833B2 JP 2014551706 A JP2014551706 A JP 2014551706A JP 2014551706 A JP2014551706 A JP 2014551706A JP 6158833 B2 JP6158833 B2 JP 6158833B2
Authority
JP
Japan
Prior art keywords
strand
beta
catenin
rnai agent
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014551706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503608A (ja
JP2015503608A5 (https=
Inventor
ヒュースケン，ディーター
ベテンコート，ブライアン
バムクロット，デイビッド
クチマンチ，サティアナラヤナ
ミルステイン，スチュアート
ジェーアール．，マイケル シラバク
ジェーアール．，マイケル シラバク
ピー． ステグマイアー，フランク
ピー． ステグマイアー，フランク
ワームス，マーカス
ウェイラー，ジャン
Original Assignee
アローヘッド ファーマシューティカルズ インコーポレイテッド
アローヘッド ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アローヘッド ファーマシューティカルズ インコーポレイテッド, アローヘッド ファーマシューティカルズ インコーポレイテッド filed Critical アローヘッド ファーマシューティカルズ インコーポレイテッド
Publication of JP2015503608A publication Critical patent/JP2015503608A/ja
Publication of JP2015503608A5 publication Critical patent/JP2015503608A5/ja
Application granted granted Critical
Publication of JP6158833B2 publication Critical patent/JP6158833B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2014551706A 2012-01-09 2013-01-08 ベータ−カテニン関連疾患を処置するための有機組成物 Active JP6158833B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261584530P 2012-01-09 2012-01-09
US61/584,530 2012-01-09
US201261598530P 2012-02-14 2012-02-14
US61/598,530 2012-02-14
PCT/IB2013/050159 WO2013105022A2 (en) 2012-01-09 2013-01-08 Organic compositions to treat beta-catenin-related diseases

Publications (3)

Publication Number Publication Date
JP2015503608A JP2015503608A (ja) 2015-02-02
JP2015503608A5 JP2015503608A5 (https=) 2016-03-03
JP6158833B2 true JP6158833B2 (ja) 2017-07-05

Family

ID=47720548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014551706A Active JP6158833B2 (ja) 2012-01-09 2013-01-08 ベータ−カテニン関連疾患を処置するための有機組成物

Country Status (9)

Country Link
US (3) US10023862B2 (https=)
EP (1) EP2802658A2 (https=)
JP (1) JP6158833B2 (https=)
CN (1) CN104302768A (https=)
AU (1) AU2013208720A1 (https=)
BR (1) BR112014016870A2 (https=)
CA (1) CA2860676A1 (https=)
HK (1) HK1205758A1 (https=)
WO (1) WO2013105022A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3134527B1 (en) * 2014-04-22 2018-12-12 Medizinische Hochschule Hannover Lncrnas for therapy and diagnosis of angiogenesis
JP6987084B2 (ja) * 2016-03-16 2021-12-22 ディセルナ ファーマシューティカルズ インコーポレイテッド β−カテニン関連疾患又は障害の治療のための組成物及び方法
JP6999664B2 (ja) * 2016-10-31 2022-01-18 サムスン ライフ パブリック ウェルフェア ファウンデーション 胆汁酸を含む虚血性再灌流損傷の予防または治療用薬学的組成物
EP3697423A4 (en) 2018-01-05 2021-08-11 Dicerna Pharmaceuticals, Inc. REDUCED EXPRESSION OF BETA-CATENIN AND IDO TO POTENTIALIZE IMMUNOTHERAPY
CN112041439A (zh) * 2018-02-14 2020-12-04 深度基因组学公司 用于威尔森病的寡核苷酸疗法
CN111500694B (zh) 2019-01-31 2023-02-24 中国科学院脑科学与智能技术卓越创新中心 Baz2b基因作为靶点在缓解衰老中的应用
TW202130809A (zh) * 2019-10-29 2021-08-16 美商愛羅海德製藥公司 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
US20240082272A1 (en) 2020-12-09 2024-03-14 The Regents Of The University Of Michigan Compositions and methods for treating wnt-driven cancer
EP4301339A2 (en) * 2021-03-01 2024-01-10 Steadman Philippon Research Institute Compositions comprising catenin mrna and their use for healing bone fractures
CA3226878A1 (en) * 2021-07-23 2023-01-26 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof
WO2025090541A1 (en) * 2023-10-25 2025-05-01 The Regents Of The University Of California Covalent degraders of oncogenic transcription factors

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696561B1 (en) 1909-07-09 2004-02-24 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5266573A (en) 1989-08-07 1993-11-30 Elf Sanofi Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999049029A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
AU776788C (en) 1998-12-16 2005-10-27 Warner-Lambert Company Treatment of arthritis with MEK inhibitors
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
IL147026A0 (en) 1999-07-09 2002-08-14 American Home Prod Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
RU2164944C1 (ru) 1999-12-09 2001-04-10 Институт молекулярной биологии им. В.А. Энгельгардта РАН Способ изменения генетических свойств организма
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
MXPA02009069A (es) 2000-03-17 2004-04-05 Benitec Australia Ltd Silenciamiento genetico.
WO2001070944A2 (de) 2000-03-22 2001-09-27 Aventis Pharma Deutschland Gmbh Nematoden als modellorganismen zur untersuchung neurodegenerativer erkrankungen und insbesonder der parkinsonschen erkrankung, verwendungen und verfahren zum auffinden von substanzen und genen, die bei der behandlung solcher erfrankungen eingesetz werden können, sowie identifizierung eines nematodengens.
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
ATE513910T1 (de) 2000-05-30 2011-07-15 Johnson & Johnson Res Pty Ltd Methoden zur gensuppression mithilfe von rnai verstärkenden faktoren
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US20030166064A1 (en) 2000-08-03 2003-09-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2002100435A1 (en) 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
CA2456977C (en) 2001-08-16 2011-06-07 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
EP2213737B1 (en) 2002-02-01 2012-11-07 Life Technologies Corporation Double-stranded oligonucleotides
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
US7375134B2 (en) 2002-03-05 2008-05-20 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
AU2003224672B2 (en) 2002-03-08 2010-02-04 Eisai R&D Management Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
MXPA05003287A (es) 2002-09-28 2005-07-05 Massachusetts Inst Technology Influenza terapeutica.
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
ES2343318T3 (es) 2002-11-26 2010-07-28 University Of Massachusetts Administracion de arnsis.
US20040208921A1 (en) 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
WO2004080406A2 (en) * 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Therapeutic compositions
CA2521464C (en) 2003-04-09 2013-02-05 Alnylam Pharmaceuticals, Inc. Irna conjugates
JP4912873B2 (ja) * 2003-04-09 2012-04-11 アルナイラム ファーマシューティカルズ， インコーポレイテッド ｉＲＮＡ複合体
ES2559828T3 (es) 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
CN1845993B (zh) 2003-08-28 2010-06-23 诺瓦提斯公司 具有平端和3＇修饰的干扰rna双链体
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
DK1789390T3 (da) 2004-09-02 2012-02-27 Genentech Inc Pyridyl-inhibitorer af hedgehog-signalering
US20090012018A1 (en) * 2004-09-13 2009-01-08 Matthias Hebrok Inhibition of pancretic cancer cell growth
CA2596845C (en) 2005-02-10 2016-11-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of diagnosing and treating cancer using b-catenin splice variants
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2008109369A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
US20100105134A1 (en) 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
EP2152879B1 (en) * 2007-05-01 2012-11-14 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
BRPI0811170B8 (pt) 2007-05-22 2021-05-25 Arcturus Therapeutics Inc oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
WO2008156702A2 (en) * 2007-06-15 2008-12-24 Cequent Pharmaceuticals, Inc. Bacteria mediated gene silencing
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
CN101854924A (zh) * 2007-11-05 2010-10-06 诺瓦提斯公司 测量wnt活化以及治疗wnt相关癌症的方法和组合物
WO2009082817A1 (en) 2007-12-27 2009-07-09 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
TWI455944B (zh) 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd 雙股多核苷酸
EP2266550A1 (en) * 2009-06-15 2010-12-29 Institut Curie Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
CA2677068A1 (en) 2009-09-01 2011-03-01 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
JP5781518B2 (ja) 2009-10-16 2015-09-24 ユニバーシティ・ヘルス・ネットワーク ポルフィリンナノ小胞
EP3000885B1 (en) 2009-12-18 2018-07-25 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
DK3037538T3 (da) 2010-07-06 2019-06-24 Dicerna Pharmaceuticals Inc Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna
CA2805265A1 (en) * 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)

Also Published As

Publication number Publication date
HK1205758A1 (en) 2015-12-24
US20150291954A1 (en) 2015-10-15
JP2015503608A (ja) 2015-02-02
BR112014016870A2 (pt) 2017-06-27
WO2013105022A2 (en) 2013-07-18
US20180282728A1 (en) 2018-10-04
AU2013208720A1 (en) 2014-07-24
WO2013105022A3 (en) 2013-10-31
EP2802658A2 (en) 2014-11-19
CA2860676A1 (en) 2013-07-18
US20250270555A1 (en) 2025-08-28
US10023862B2 (en) 2018-07-17
CN104302768A (zh) 2015-01-21

Similar Documents

Publication Publication Date Title
US20250270555A1 (en) Organic compositions to treat beta-catenin-related diseases
US12091661B2 (en) Organic compositions to treat HSF1-related diseases
JP6577073B2 (ja) ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
US11261444B2 (en) Organic compositions to treat EPAS1-related diseases
AU2017268399A1 (en) Mrna combination therapy for the treatment of cancer
KR20140057374A (ko) Hsf1-관련 질환을 치료하기 위한 유기 조성물
TW202227101A (zh) 用於調節血管收縮素原表現之化合物及方法
WO2022026648A1 (en) Inhibition of incexact1 to treat heart disease
CN120456911A (zh) 用于抑制补体组分C3(C3)表达的RNAi剂、其药物组合物及使用方法
CN121152878A (zh) 用于抑制补体因子B (CFB)表达的RNAi剂、其药物组合物和使用方法

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170508

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170608

R150 Certificate of patent or registration of utility model

Ref document number: 6158833

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250